Thiamine-responsive megaloblastic anaemia in a young adult with acute pancytopenia
- PMID: 39353666
- DOI: 10.1136/bcr-2024-261435
Thiamine-responsive megaloblastic anaemia in a young adult with acute pancytopenia
Abstract
Thiamine-responsive megaloblastic anaemia (TRMA) is a rare autosomal recessive disorder characterised by the clinical triad of megaloblastic anaemia, sensorineural hearing loss and diabetes mellitus (DM) in young patients. We present a case of a young man with type 1 DM who presented with pancytopenia of unclear aetiology, initially attributed to a COVID-19 infection. After obtaining a bone marrow biopsy and pursuing genetic testing, two pathogenic variants of the SLC19A2 gene consistent with TRMA were discovered in this patient. Treatment with 100 mg of thiamine oral supplementation daily led to the complete resolution of his pancytopenia. It is important to consider a genetic cause of pancytopenia in a young person. Early recognition and diagnosis of TRMA can be life-altering given early treatment can reduce insulin requirements and resolve anaemia.
Keywords: General practice / family medicine; Genetic screening / counselling; Genetics; Haematology (incl blood transfusion).
© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources